Despite Treatments, Diabetes Cases on the Rise in the U.S., Demand for Incretin Therapies Steadily Growing

April 08, 2015

Wellesley, Mass., April 08, 2015 –BCC Research ( reveals in its new report on incretin-based therapeutics that diabetes, connected to obesity, is and has been on the rise globally, and new treatments are being developed and used to deal with the varying types and stages. It is a chronic disease whereby blood sugar cannot be effectively regulated because the pancreas does not produce enough insulin or the body cannot effectively use insulin.

According to the American Diabetes Association, 29.1 million Americans — 21 million of who were diagnosed and 8.1 million of who were undiagnosed — had diabetes in 2012, with the vast majority (approximately 90%) having Type 2 diabetes. The World Health Organization (WHO) projects deaths from diabetes to double globally from 2005 to 2030 in part due to increasing rates of obesity around the world. Given that half of diabetes patients — 90% of whom have Type 2 diabetes that may or may not require insulin — do not have adequate control over their blood sugar despite taking medications, a need exists for improved therapies.

Despite the numbers of diabetics and treatments, nearly 50% of patients with this condition fail to meet their glycemic target. To counteract this situation, incretin-based therapies are designed to further provide glycemic control for diabetics when diet, exercise and possibly a first-line therapy such as metformin are not adequate. They can be stand-alone treatments that, in some cases, even delay the start of insulin or reduce the need for it, and can also augment actual insulin therapy itself or other medications such as metformin.

The field of incretin-based therapies, also called incretin mimetics or incretin enhancers, has moved in the span of the last decade to be at the forefront of glycemic control in diabetes patients worldwide. “The prescription volume for incretin-based therapies has been steadily rising, particularly because so many diabetes patients are failing to reach goals for blood sugar levels (HbA1c, glycated hemoglobin expressed as either HbA1c or A1c),” says BCC Research analyst Kim Lawson. “Beyond glycemic control, incretin-based therapies, particularly GLP-1 receptor agonists, offer weight loss promotion and possibly cardioprotective attributes.”

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments includes the growth potential for incretin-based therapies over a five-year period from 2014 through 2019. The key objective is to present a comprehensive analysis of the current therapy technology and drug development market and its future direction, with the aim to first define and classify that technology as it pertains to therapeutics.


To Contact us, click here  help

Source: BCC Research

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments( PHM162A )
Publish Date: Feb 2015    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.